SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is drawing attention after VK2735 study data showed patients maintained most of their weight loss on less-frequent injections, bolstering optimism about the obesity drugs potential. Traders are celebrating the results and analyst support, while debating the stocks follow-through, possible dilution, and speculative partnership or buyout prospects.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs reported real-time quantum error-correction decoder running on a standard CPU is drawing the most attention, with bulls calling it progress toward fault-tolerant computing and skeptics stressing that it does not demonstrate a comparable large-scale quantum computer in hardware. Traders are also discussing the SDT partnership to deploy IonQ systems and expand manufacturing in South Korea.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions integration of its qLDPC library with NVIDIA CUDA-Q Logical is drawing attention, with the company reporting an error-correction approach that uses roughly five times fewer physical qubits than the surface-code benchmark. Traders view the development as a potential technical validation, but debate why the stock has not responded more strongly amid volatile quantum-sector trading and broader market pressure.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyagers proposed $350 million convertible senior notes offering is driving attention, with traders concerned about potential dilution and frustrated by what they see as repeated fundraising. Some view the selloff as a buying opportunity, but the dominant reaction is negative.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp move higher toward the $0.10 level has traders discussing a possible technical breakout, while some speculate that expectations around the CLARITY Act are helping sentiment. The reaction is mixed: bulls see renewed momentum, while skeptics question whether the move can hold and point to resistance and previous failed rallies.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

Reports that Royal Caribbean is nearing a deal to take control of Sandals Resorts have fueled the selloff, with traders debating the cost and potential debt or share dilution. Some see the acquisition as a costly distraction, while others view Sandals resort business as a profitable strategic fit with cross-selling potential.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Cantor Fitzgeralds upgrade, citing stronger-than-expected commercial potential for Yartemlea, is the main catalyst behind OMERs surge. Traders are broadly bullish on the drugs launch and sales prospects, while some speculate that institutional buying or other upcoming catalysts may also be contributing; those explanations remain unconfirmed.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermis TensorWave lease closing deadline was extended by a month, while the anticipated financing backstop remains unresolved after management had suggested it was near; traders worry the delay could put the deal or counterparty commitment at risk. Some blame the former CEO-board dispute for complicating negotiations, while others view the extension as a chance for the lease and broader AI-power project to proceed.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs sharp move is drawing attention amid speculation about founder Patrick Soon-Shiongs teased blockchain-based stock-trading plans and whether IBRX could eventually be tokenized; bullish traders say this could constrain short selling, while skeptics note no IBRX tokenization has been announced. Traders are also speculating that Soon-Shiongs meeting with Turkeys president could lead to Anktiva expansion there, but no approval or deal is confirmed.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

PENGUs sharp rally and move above the one-cent level are drawing attention, with traders celebrating the breakout and hoping for more upside. Others warn that the move may be temporary and point to the tokens history of sharp pullbacks; speculation about future brand developments and an ETF remains unconfirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BMY vs GILD: Which Biotech Stock Looks More Attractive Now? 

Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.



J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?

JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America

GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120...

ITOC Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against iTonic Holdings Ltd.

ITOC Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against iTonic Holdings Ltd. ITOC Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against iTonic Holdings Ltd.PR NewswireSAN DIEGO, Sept. 15, 2026...

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through...

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers   New York, NY – September 15, 2026 – Market News Updates News Commentary – The antiviral market is entering a period where the need for new treatments is becoming impossible […]
The post A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat appeared first on Financial News Media.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.

If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annualized basis producing an average annual return of 11.56%. Currently, Gilead Sciences has a market capitalization ofread more...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict  

Equity

Bearish Sentiment

Track GILD stock price, charts, news and real-time market activity on Stocktwits. Join the GILD message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Gilead Sciences, Inc stock.

GILD Stock Price Today - Gilead Sciences, Inc News, Charts, Retail Sentiment

Job displacement

Market bubble / overvaluation

Loss of human oversight / control

Killer robots 🤖

As AI spending accelerates across hyperscalers and valuations climb to historic highs, investors and workers alike are increasingly debating the risks the technology poses - from job displacement to fears about losing human oversight over increasingly autonomous systems. What do you think is the biggest threat AI poses? Vote and explain your reasoning in the comments.

Current Price	$152.67
Prev Close	$150.56
Open	$150.65
Dividend Yield	2.57%
50-Day Moving Average	$139.97
Beta	0.35
Avg. Volume	6.35M
PE Ratio	-56.68

52-Week High	$157.29
52-Week Low	$108.46
Market Capitalization	$186.69B
EPS (Annual)	$6.78
Price to Book	15.80
Revenue Per Employee	$1.73M

Feed

News

Sentiment

Earnings

Fundamentals

Info

GILD Fundamentals